Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
Products
Automate
Trackers
Innovation Services
About Index
Index
By TNW
Log in
Register
Syndesi Therapeutics
228
Syndesi Therapeutics
Technology
Biotechnology
Health Care
Medical
Therapeutics
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain).
Suggest edits
Type
B2c
Founded
2018
Raised
$21M
Follow us
Also headquartered in Louvain-La-Neuve
Qualifio
Keemotion
Vives Fund
InternetVista
GetSmily
Elimity
Vives Louvain Technology Fund
Lean FUND
Tessares
WinBooks
Companies in the same industry
Lunac Therapeutics
EnClear Therapies
Eureka Therapeutics
AZTherapies
Biomoti
Complexa
PDC*line Pharma
Confo Therapeutics
ELSALYS BIOTECH
Kyn Therapeutics
Alexa global traffic share
Overview
Funding
1
Add info
Latest funding
€17,000,000
Venture capital (Series A) - 2018
Johnson & Johnson Innovation
Fountain Healthcare Partners
Johnson & Johnson
+3
Team Size
2
Employees
I work here
Location
Louvain-La-Neuve
,
Belgium
Headquarters
Explore Louvain-La-Neuve
€17,000,000
Venture capital (Series A)
FierceBiotech
UCB spins out neuro startup with €17M from Novo, Johnson & Johnson
